Comparison of clinical characteristics at diagnosis and during follow-up in 118 patients with Hurthle cell or follicular thyroid cancer

被引:64
|
作者
Kushchayeva, Yevgeniya [1 ]
Duh, Quan-Yang [1 ]
Kebebew, Electron [1 ]
D'Avanzo, Alessandra [1 ]
Clark, Orlo H. [1 ]
机构
[1] Univ Calif San Francisco, Mt Zion Med Ctr, Dept Surg, San Francisco, CA 94143 USA
来源
AMERICAN JOURNAL OF SURGERY | 2008年 / 195卷 / 04期
关键词
Hurthle cell; follicular cancer; risk factors;
D O I
10.1016/j.amjsurg.2007.06.001
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Hurthle cell cancer (HCC) is considered by some to be a variant of follicular cancer (FC), but many think it is a distinct histologic tumor with a more aggressive behavior. Methods: The influence of age at diagnosis, tumor stage, gender, and extent of operation on disease-free interval and cause-specific mortality at 5 and 10 years after initial thyroidectomy was analyzed. Results: The 10-year disease-free interval was 75% for FC and 40.5% for HCC (P = .08). The 10-year cause-specific mortality was 20% for FC patients and 51% for HCC (P = .2). The risk factors for HCC progression and survival were extrathyroidal invasion, presence of metastases at diagnosis, male gender, and extent of thyroidectomy, whereas for FC, the only significant risk factors were extrathyroidal invasion and presence of metastases at diagnosis. Conclusion: Patients with HCC have more aggressive tumors than patients with FC. Our data suggest that FC and HCC should be classified as distinct tumors. (c) 2008 Elsevier Inc. All rights reserved.
引用
收藏
页码:457 / 462
页数:6
相关论文
共 50 条
  • [31] The follow-up of patients with differentiated thyroid cancer and undetectable Tg and TgAb during ablation
    Phan, H. T. T.
    Jager, P. L.
    van der Wal, J. E.
    Sluiter, W. J.
    Plukker, J. T. M.
    Dierckx, R. A. J.
    Wolffenbuttel, B. H. R.
    Links, T. P.
    HORMONE RESEARCH, 2007, 68 : 30 - 31
  • [32] Diagnosis, staging and follow-up in breast cancer patients
    Stickeler, Elmar
    BREAST CARE, 2007, 2 (03) : 158 - 162
  • [33] Clinical characteristics and follow-up in patients with microvascular angina
    Suzuki, H
    Matsubara, H
    Koba, S
    Murakami, M
    Takeyama, Y
    Katagiri, T
    CIRCULATION JOURNAL, 2002, 66 (07) : 691 - 695
  • [34] Follow-up and Outcomes of 186 Patients With Follicular Cell-Derived Thyroid Cancer Seen at a Referral Center by One Thyroidologist in 2015
    Fatourechi, Vahab
    ENDOCRINE PRACTICE, 2024, 30 (05) : 450 - 455
  • [35] SIGNIFICANCE OF THE CARCINOEMBRYONIC ANTIGEN (CEA) IN THE PREOPERATIVE DIAGNOSIS AND IN THE FOLLOW-UP OF PATIENTS WITH THYROID-CANCER
    MADEDDU, G
    LANGER, M
    DETTORI, G
    COSTANZA, C
    ARRAS, ML
    JOURNAL OF NUCLEAR MEDICINE AND ALLIED SCIENCES, 1979, 23 (04): : 215 - 216
  • [36] A COMPLEX FOLLOW-UP PROGRAM FOR THYROID-CANCER PATIENTS
    REINERS, C
    BORNER, W
    MEDIZINISCHE KLINIK, 1982, 77 (18) : 515 - 519
  • [37] Lobectomy in patients with differentiated thyroid cancer: indications and follow-up
    Park, Jae Hyun
    Yoon, Jong Ho
    ENDOCRINE-RELATED CANCER, 2019, 26 (07) : R381 - R393
  • [38] Proportion of patients with idiopathic dilated cardiomyopathy and SCDHeFT characteristics on diagnosis and during follow-up
    Zecchin, M.
    Gregori, D.
    Di Lenarda, A.
    Pivetta, A.
    Merlo, M.
    Sinagra, G.
    JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2007, 18 : S27 - S28
  • [39] FDG PET in the follow-up of patients with differentiated thyroid cancer
    Szakall, S
    Ésik, O
    Emri, M
    Füzy, M
    Tóth, E
    Forrai, G
    Trón, L
    RADIOACTIVE ISOTOPES IN CLINICAL MEDICINE AND RESEARCH XXIII, 1999, : 475 - 478
  • [40] Current concepts in the follow-up of patients with differentiated thyroid cancer
    Benbassat, Carlos A.
    Mechlis-Frish, Sara
    Guttmann, Hadassah
    Glaser, Benjamin
    Krausz, Yodphat
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2007, 9 (07): : 540 - 545